MacroGenics (MGNX) FDA Approvals

MacroGenics logo
$1.96 -0.03 (-1.26%)
As of 03:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MacroGenics' Drugs in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by MacroGenics (MGNX). Over the past two years, MacroGenics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as MGC026, MGC030, and lorigerlimab. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Select a button below to view the list of FDA events for that drug.

MGC026 FDA Regulatory Events

MGC026 is a drug developed by MacroGenics for the following indication: in patients with advanced solid tumors. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

MGC030 FDA Regulatory Events

MGC030 is a drug developed by MacroGenics for the following indication: In Patients With Advanced Solid Tumors. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Lorigerlimab FDA Regulatory Events

Lorigerlimab is a drug developed by MacroGenics for the following indication: In patients with mCRPC. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

MacroGenics FDA Events - Frequently Asked Questions

In the past two years, MacroGenics (MGNX) has not received FDA approval for any therapies. However, the company does have drugs under review or in active clinical development.

In the past two years, MacroGenics (MGNX) has reported FDA regulatory activity for the following drugs: lorigerlimab, MGC026 and MGC030.

The most recent FDA-related event for MacroGenics occurred on October 23, 2026, involving MGC026. The update was categorized as "Interim Data," with the company reporting: "MacroGenics, Inc. announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain."

Current therapies from MacroGenics in review with the FDA target conditions such as:

  • In patients with mCRPC - lorigerlimab
  • in patients with advanced solid tumors - MGC026
  • In Patients With Advanced Solid Tumors - MGC030
  • NDA: New Drug Application
  • ANDA: Abbreviated New Drug Application
  • sNDA: Supplemental New Drug Application
  • BLA: Biologics License Application
  • sBLA: Supplemental Biologics License Application
  • FDA Approved: Approved by the FDA
  • EMA: European Medicines Agency
  • CE Mark: European Union Certification
  • NMPA: China National Medical Products Administration
  • MHLW: Japanese Ministry of Health
  • FDA Meeting: Consultation with FDA
  • Pre-IND: Pre-Investigational New Drug Meeting
  • Breakthrough Therapy: Special FDA designation for promising therapies
  • Fast Track: Accelerated FDA approval pathway
  • Orphan Drug: Designation for rare disease treatments
  • RPD: Rare Pediatric Disease Designation
  • RMAT: Regenerative Medicine Advanced Therapy
  • DSMB Review: Data Safety Monitoring Board Review
  • IDMC Review: Independent Data Monitoring Committee
  • MAA: MHRA Marketing Authorization Application
  • RTF: Refusal to File (Rejected Application)
  • 510(k): FDA Clearance for Medical Devices
  • Rolling Submission: Staggered regulatory review process

FDA progress for NASDAQ:MGNX last updated on 10/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.
From Our Partners